Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pfirrmann

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Seminars in Hematology|February 4, 2003
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapyJ Hasford, M Pfirrmann, R Hehlmann, et al.
Leukemia|April 15, 2005
Gender aspects in chronic myeloid leukemia: long-term results from randomized studiesU Berger, O Maywald, M Pfirrmann, et al.
Leukemia|June 12, 2013
The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinibV S Hoffmann, M Baccarani, D Lindoerfer, et al.
Leukemia|October 17, 2003
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trialG Buesche, R Hehlmann, H Hecker, et al.
Leukemia|December 8, 2010
Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trialF Stölzel, M Pfirrmann, W E Aulitzky, et al.
Leukemia|February 3, 2006
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemiaO Maywald, M Pfirrmann, U Berger, et al.
Leukemia|July 31, 2004
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemiaG Buesche, M Freund, R Hehlmann, et al.
Leukemia|September 13, 2003
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alphaU Berger, G Engelich, O Maywald, et al.
Leukemia|July 28, 2023
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trialJ Hammersen, S Birndt, K Döhner, et al.
Leukemia|October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosisM Jawhar, J Schwaab, S Schnittger, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Seminars in Hematology|February 4, 2003
Prognosis and prognostic factors for patients with chronic myeloid leukemia: nontransplant therapyJ Hasford, M Pfirrmann, R Hehlmann, et al.
Leukemia|April 15, 2005
Gender aspects in chronic myeloid leukemia: long-term results from randomized studiesU Berger, O Maywald, M Pfirrmann, et al.
Leukemia|June 12, 2013
The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinibV S Hoffmann, M Baccarani, D Lindoerfer, et al.
Leukemia|October 17, 2003
Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia - prospective long-term results from a randomized-controlled trialG Buesche, R Hehlmann, H Hecker, et al.
Leukemia|December 8, 2010
Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trialF Stölzel, M Pfirrmann, W E Aulitzky, et al.
Leukemia|February 3, 2006
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemiaO Maywald, M Pfirrmann, U Berger, et al.
Leukemia|July 31, 2004
Treatment intensity significantly influencing fibrosis in bone marrow independently of the cytogenetic response: meta-analysis of the long-term results from two prospective controlled trials on chronic myeloid leukemiaG Buesche, M Freund, R Hehlmann, et al.
Leukemia|September 13, 2003
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alphaU Berger, G Engelich, O Maywald, et al.
Leukemia|July 28, 2023
The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trialJ Hammersen, S Birndt, K Döhner, et al.
Leukemia|October 15, 2015
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosisM Jawhar, J Schwaab, S Schnittger, et al.
Pageof 4